Duchenne muscular dystrophy (DMD)

Manila folder with CONFIDENTIAL printed on it in red
Biotech

Capricor responds to cell therapy snub, disputes FDA’s concerns

Capricor called the rejection "difficult to understand" because the FDA had originally okayed the company's submission plan.
Darren Incorvaia Sep 9, 2025 11:44am
boardroom

Keros shakes up leadership structure to go all in on DMD drug

Aug 7, 2025 6:15am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

FDA contemplates pulling Sarepta’s Elevidys from market

Jul 18, 2025 3:10pm
Businessman about to be crushed by falling dominos

Sarepta overhaul includes 500 layoffs, gene therapy program cuts

Jul 16, 2025 4:59pm
Graphic image of a red thumbs down against a blue background

FDA rejects Capricor’s DMD cell therapy, asks for more data

Jul 11, 2025 9:18am